Mostrar el registro sencillo del ítem

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

dc.contributor.authorSychev D.A.
dc.contributor.authorAshraf G.M.
dc.contributor.authorSvistunov A.A.
dc.contributor.authorMaksimov M.L.
dc.contributor.authorTarasov V.V.
dc.contributor.authorChubarev V.N.
dc.contributor.authorOtdelenov V.A.
dc.contributor.authorDenisenko N.P.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:28:49Z
dc.date.available2020-09-02T22:28:49Z
dc.date.issued2018
dc.identifier10.2147/DDDT.S149069
dc.identifier.citation12, , 1147-1156
dc.identifier.issn11778881
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6356
dc.descriptionCytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drugs are important and clinically relevant pharmacokinetic mechanisms of drug interaction. Investigation of the activity of CYP isoenzymes by using phenotyping methods (such as the determination of the concentration of specific substrates and metabolites in biological fluids) during drug administration provides the prediction of negative side effects caused by drug interaction. In clinical practice, the process of phenotyping of CYP isoenzymes and some endogenous substrates in the ratio of cortisol to 6β-hydroxycortisol in urine for the evaluation of CYP3A4 activity has been deemed to be a quite promising, safe and minimally invasive method for patients nowadays. © 2018 Sychev et al.
dc.language.isoen
dc.publisherDove Medical Press Ltd.
dc.subjectCytochrome CYP450
dc.subjectDrug interaction
dc.subjectDrug metabolism
dc.subjectPhenotyping
dc.subjectalprazolam
dc.subjectatorvastatin
dc.subjectcaffeine
dc.subjectcelecoxib
dc.subjectclozapine
dc.subjectcodeine
dc.subjectcytochrome P450 1A2
dc.subjectcytochrome P450 2C19
dc.subjectcytochrome P450 2C9
dc.subjectcytochrome P450 2D6
dc.subjectcytochrome P450 3A4
dc.subjectdextromethorphan
dc.subjectdiazepam
dc.subjecthexobarbital
dc.subjectlosartan
dc.subjectmetoprolol
dc.subjectnortriptyline
dc.subjectomeprazole
dc.subjectpantoprazole
dc.subjectparacetamol
dc.subjectphenacetin
dc.subjectphenytoin
dc.subjectpravastatin
dc.subjectpropafenone
dc.subjecttestosterone
dc.subjecttheophylline
dc.subjecttolbutamide
dc.subjectunindexed drug
dc.subjectwarfarin
dc.subjectzidovudine
dc.subject6 beta-hydroxycortisol
dc.subjectcytochrome P450
dc.subjecthydrocortisone
dc.subjectisoenzyme
dc.subjectdrug metabolism
dc.subjectdrug transformation
dc.subjectenzyme activity
dc.subjectenzyme inhibition
dc.subjectenzyme specificity
dc.subjecthuman
dc.subjecthydrophilicity
dc.subjecthydrophobicity
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectphenotype
dc.subjectprediction
dc.subjectprotein expression
dc.subjectprotein function
dc.subjectReview
dc.subjectsingle nucleotide polymorphism
dc.subjectanalogs and derivatives
dc.subjectbiotransformation
dc.subjectdrug interaction
dc.subjectmetabolism
dc.subjectBiotransformation
dc.subjectCytochrome P-450 Enzyme System
dc.subjectDrug Interactions
dc.subjectHumans
dc.subjectHydrocortisone
dc.subjectIsoenzymes
dc.subjectPhenotype
dc.titleThe cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85046669972.pdf
Tamaño:
3.731Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem